Active Pass Pharmaceuticals Announces the Appointment of David MacDonald, PhD to the Position of Vice President, Research & Development.Business Editors/Health & Medical Writers BIOWIRE 2K VANCOUVER, British Columbia--(BW HealthWire)--Sept. 17, 2001 Active Pass Pharmaceuticals announces the appointment of David MacDonald, PhD to the position of Vice President, Research & Development. With over 12 years of experience in the pharmaceutical industry, Dr. MacDonald brings to the Company a wealth of experience in several aspects of drug development, from basic research through clinical trials. Commenting on the appointment, Peter B. Reiner, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Active Pass, stated, "We are delighted to have someone of David's caliber join us as we continue to build excellence into our senior management team." Dr. MacDonald was most recently General Manager of Biovail Contract Research at Biovail Corporation where he was responsible for the clinical research division which included over 200 employees. Prior to his tenure at Biovail, Dr. MacDonald held positions of increasing responsibility at Syntex and Hemosol. Dr. MacDonald obtained his BSc in Chemistry from the University of Prince Edward Island The university was incorporated in 1969 with the merger of its predecessor institutions, Prince of Wales College (PWC) and St. Dunstan's University (SDU). Its campus is located on the SDU campus. , and his PhD in Physical Chemistry from the University of Alberta. Active Pass Pharmaceuticals is a privately held biotechnology company engaged in genomic-based drug discovery. The Company's principal activity is the discovery and early clinical development of novel therapeutics that target a biologically important family of molecular pumps known as ABC ABC in full American Broadcasting Co. Major U.S. television network. It began when the expanding national radio network NBC split into the separate Red and Blue networks in 1928. transporters. Responsible for the movement of diverse compounds across biological membranes, individual ABC transporters have already been shown to be validated targets for human diseases, including Alzheimer's, macular degeneration macular degeneration, eye disorder causing loss of central vision. The affected area, the macula, lies at the back of the retina and is the part that produces the sharpest vision. , hypercholesterolemia Hypercholesterolemia Definition Hypercholesterolemia refers to levels of cholesterol in the blood that are higher than normal. Description Cholesterol circulates in the blood stream. It is an essential molecule for the human body. , cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. , and diabetes, among others. Moreover, ABC transporters are well known to be involved in the absorption and excretion of endo- and xenobiotic xen·o·bi·ot·ic adj. Foreign to the body or to living organisms. Used of chemical compounds. n. A xenobiotic chemical. xenobiotic any substance, harmful or not, that is foreign to the animal's biological system. compounds, providing additional opportunities for drug development. Active Pass has put into place an Alzheimer's therapeutic program that targets brain-expressed ABC transporters, and is pursuing new opportunities utilizing a chemogenomic strategy. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion